Vasostatin-Apo2L

**Vasostatin-Apo2L** is an investigational recombinant fusion protein developed as a potential anticancer therapy by Aida Pharmaceuticals through its Shanghai Qiaer Biotechnology subsidiary. It combines a vasostatin fragment, intended to inhibit endothelial-cell proliferation, angiogenesis, and tumor growth, with an Apo2L component corresponding to recombinant TNF-related apoptosis-inducing ligand that is intended to induce apoptosis in susceptible tumor cells through death-receptor signaling. Public company disclosures described the program as being in preclinical research; no marketing authorization, clinical dosage form, or completed clinical development program for Vasostatin-Apo2L was identified.

Other names

Vasostatin Apo2L